<DOC>
	<DOCNO>NCT00843011</DOCNO>
	<brief_summary>This study open-label , randomise , single dose study determine pharmacokinetics , safety tolerability 2 different formulation orvepitant 60 mg effect food 15 Healthy Volunteers .</brief_summary>
	<brief_title>Food Relative Bioavailability Study</brief_title>
	<detailed_description>Orvepitant highly potent selective neurokinin-1 ( NK1 ) receptor antagonist currently development treatment depression anxiety . This study open-label , randomise , single dose study determine pharmacokinetics , safety tolerability 2 different formulation orvepitant 60 mg effect food 15 Healthy Volunteers . According cross design , three different occasion , subject receive `` old '' formulation orvepitant fast condition `` new '' formulation fast condition FDA High-Fat Breakfast . Subjects screen within 21 day first treatment . On dose occasion , subject admit clinic Day-1 remain Day 2 ; also ask return site 48 72 hour dose PK blood sample collection . The wash-out period dose occasion least 5 day subject ask return site 7-14 day administration last dose orvepitant follow-up visit .</detailed_description>
	<criteria>Healthy male female 18 65 year age inclusive . A female subject eligible participate either nonchildbearing potential childbearing potential agrees use one contraception methods No comorbid Psychiatric Disorders define use Mini International Neuropsychiatric Interview ( M.I.N.I ) scale . A 12lead ECG screening show abnormality opinion Principal Investigator compromise safety study . Body weight â‰¥ 50 kg BMI within range 19.0 29.9 kg/m2 ( inclusive ) . Capable give write informed consent As result medical interview , physical examination screen investigation Physician Responsible considers subject unfit study . The subject history drug allergy opinion Physician Responsible contraindicate participation study . Subjects unstable medical disorder disorder would likely interfere action , absorption , distribution , metabolism excretion orvepitant , may pose safety concern , interfere accurate assessment safety . The subject current recent ( within six month ) document gastrointestinal disease ; history malabsorption , oesophageal reflux , irritable bowel syndrome ; frequent ( week ) occurrence heartburn , surgical intervention ( e.g . cholecystectomy ) would expect influence absorption drug . History psychiatric illness Any history clinically significant abnormality neurological system ( include dementia cognitive disorder significant head injury ) history seizure ( exclude febrile seizure ) . Subject consume alcool tobacco Subject positive Hepatitis B , C HIV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>NK1 antagonist</keyword>
	<keyword>effect food</keyword>
	<keyword>safety tolerability</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>formulation</keyword>
</DOC>